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Introduction  
Laminitis is a debilitating clinical syndrome of lameness due to hoof pain that equine 
practitioners are very familiar with. However, it has only been in the last decade that distinct 
causes of laminitis have been well defined and the importance of endocrine causes of 
laminitis, including laminitis associated with pituitary pars intermedia dysfunction (PPID) 
have been understood.1 This in depth paper will discuss laminitis, focusing on 
endocrinopathic laminitis and the intersection of PPID and laminitis.  
Causes of laminitis  
Research has stratified laminitis as occurring from 3 main causes: SIRS or sepsis associated 
laminitis including enterocolitis, pleuropneumonia, retained fetal membranes and grain 
overload; supporting limb laminitis; and endocrinopathic laminitis. 1  
Historically, laminitis research was focused on conditions causing severe systemic 
inflammation (SIRS) or sepsis, such as carbohydrate overload or metritis. Notably, Obel’s  
1948 thesis used both a starch overload and a metritis model to study laminitis. 2 Between 
1948 and the last decade, laminitis research involved exclusively SIRS models including: 
starch overload 3, black walnut extract 4 and oligofructose overload 5. The severe SIRS or 
sepsis associated form of laminitis was assumed to be more common, since it was more 
commonly seen at the university hospitals where most of the laminitis research had been 
conducted. 6 Systemic endocrine disease was known to be associated with laminitis but  
received relatively little attention. 7,8    
Yet horse owners and frontline practitioners were telling a different story. In a large 
epidemiological study in the USA involving over 20,000 horses, 9 it was found that causes of 
laminitis reported by their owners that were associated with SIRS or sepsis related conditions 
including grain overload, retained placenta, colic or diarrhea only accounted for 12% of the 
cases of laminitis, with the majority of cases reported as associated with dietary problems, 
obesity or “unknown”. Studies in Europe 10 and the USA 11 showed convincing evidence that 
the endocrine disorders account for over 90% of horses presenting with lameness due to 
laminitis. Finally, researchers showed unequivocally that infusion of insulin induced laminitis 
in healthy, lean ponies 12 or Standardbred racehorses.13 They also showed that infusion of 
glucose causing mild hyperglycemia and endogenous hyperinsulinemia resulted in laminitic 
hoof lesions (without lameness). 14 This combined with some excellent field  
research looking at predispositions for laminitis in ponies in the USA 15, 16 all supported the 
conclusion that laminitis could occur without pro-inflammatory and intestinal conditions; 
fitting in with the term endocrinopathic laminitis that had been coined a few years earlier. 17  
Endocrinopathic laminitis  
There are two main conditions associated with endocrinopathic laminitis, pituitary pars 
intermedia dysfunction (PPID) and equine metabolic syndrome (EMS). Common to both 
these conditions appears to be the development of insulin dysregulation.  Insulin 
dysregulation results in hyperinsulinemia (either basally, or in association with the ingestion 
of carbohydrates in forages and feeds). 18  
PPID is a disease of aged horses characterized by loss of dopaminergic inhibition of the 
pituitary pars intermedia and resultant overproduction of pituitary hormones 
(adrenocorticotropin [ACTH], alpha melanocyte stimulating hormone [α-MSH], beta 
endorphin [β-endorphin] and corticotrophin-like intermediate peptide [CLIP]). The resultant 
clinical syndrome is variably associated with a wide array of clinical signs including 
hypertrichosis and abnormal hair shedding patterns, laminitis, muscle wastage, abnormal fat 
distribution, polyuria and polydipsia, increased susceptibility to infections and infertility. 19 
EMS has been defined in the 2010 ACVIM consensus statement as a phenotype of obesity 
(regional or generalised), insulin resistance (hyperinsulinemia or abnormal insulin and 
glucose regulation; now known as insulin dysregulation18) and a predisposition to laminitis 
that has developed in the absence of recognised causes such as grain overload, colic, colitis, 
or retained placenta. 20 
Laminitis and PPID  
Laminitis has been frequently diagnosed in horses with PPID and laboratory submissions 
suggest it is a common trigger for horse owners to request veterinary investigation of cases of 
PPID. 21 On pooled analysis from 13 studies, laminitis was the second most common clinical 
sign in horses with PPID (49%), second only to hypertrichosis (70%). 22 Horses with PPID 
have 4.65 times the odds of developing laminitis compared to aged matched controls. 23 Yet 
laminitis occurs variably in studies from 8-82%. 22 This finding may seem conflicting, but 
can be explained by a number of factors.   
a. Firstly, it appears insulin dysregulation is key to develop of laminitis in PPID-affected 
horses. This is supported by histological research that showed that laminar lesions only 
occurred in horses with PPID and hyperinsulinemia, and not in horses with PPID but 
normal basal insulin concentrations. 24 An epidemiological study demonstrated that over a 
third of horses with PPID had hyperinsulinemia, and 67% of horses with PPID and 
laminitis had basal hyperinsulinemia 23. Horses with PPID were 2.7 times more likely to 
have hyperinsulinemia than aged matched controls. 23 However, when basal 
hyperinsulinemia occurred in PPID or non-PPID aged horses, they were equally at risk 
for developing laminitis. 23  
b. Secondly, even when horses are insulin dysregulated, laminitis may not produce clinical 
lameness. Histological research in naturally occurring cases of endocrinopathic laminitis 
showed no relationship between the duration of clinical lameness and the degree of 
pathology found histologically, but did identify the consistent presence of hoof capsular 
changes in association with pathology such as divergent hoof rings. 27 This was supported 
by epidemiological research in aged horses where hoof abnormalities indicative of 
chronic laminitis (including dropped soles, laminitic rings and separated white lines) were  
more prevalent than a history of laminitis 23, 28. This implies that horses can have repeated 
subclinical bouts of laminitis without lameness, which may not be identified or may not 
be considered significant by horse owners.  
c. Thirdly, the presentation of horses with PPID for veterinary attention requires the 
recognition of the clinical signs of PPID by their owners. Epidemiological research has 
shown that many of the clinical signs of PPID are considered normal signs of aging by 
horse owners, including hypertrichosis and muscle atrophy. 29 Indeed, in one study, only 
1.6% of horse owners reported their horses with PPID, yet 21.2% tested positive on 
seasonally adjusted basal ACTH measurements. 23 This may well explain the large 
category of “unknown” laminitis cases back in the 1990’s when horse owners were asked 
to identify the causes of laminitis in their horses. 9 Laminitis, at least where it causes 
lameness, is more likely to result in horses being presented for veterinary attention, 
therefore, if research studies or case series used owner presented animals for inclusion in  
studies, the prevalence of laminitis is likely to be higher. 21,22  
Insulin dysregulation and laminitis  
It is now well established that hyperinsulinemia associated with insulin dysregulation causes 
laminitis in affected horses, especially when challenged by dietary carbohydrates. Laminitis 
has been linked to insulin resistance and hyperinsulinemia in field studies since the 1980’s. 7, 
8, 15, 16, 30 Experimental research has shown a direct link between hyperinsulinemia and  
laminitis. 12,13 Laminitis was induced in 100% of normal ponies 12 or horses 13 exposed to 
high concentrations of insulin (> 1000 µIU/ml) while maintaining euglycemia of 5 mmol/l 
using a modified euglycemic-hyperinsulinemic clamp technique. All treated ponies or horses 
were healthy, young and non-obese, with no history of laminitis and no evidence of endocrine 
or other abnormalities on blood tests. Laminitis occurred slowly and in all 4 limbs, with the 
onset of lameness associated with laminitis (Obel grade 2) occurring by approximately 48 
hours. There was no evidence of gastrointestinal involvement or systemic illness throughout  
the experiments. 12,13  
The hyperinsulinemic model of laminitis has allowed us to explore different mechanisms that 
are possibly involved in the development of endocrinopathic laminitis. Prior research does 
not support glucose deprivation 31 or glucose excess 32 as underlying mechanisms.  
Metalloproteinases (MMP2 and MMP9 and ADAMTS4) have been consistently upregulated 
in SIRS or sepsis models of laminitis. 33 However, this has not been the case in 
hyperinsulinemic laminitis where minimal MMP or ADAMTS4 activity during the 
developmental and acute stages of laminitis occurred and only MMP9 was upregulated at 
later stages of laminitis (48 hours), correlating with histological evidence of neutrophil 
infiltration. 34  
Mechanisms of hyperinsulinemia and laminitis  
More recently insulin’s effect on signaling within cells and its effects on blood flow have 
provided important mechanistic clues. Insulin, when it is working via its appropriate 
intracellular pathways, has marked effects on stimulating vasodilation and blood flow in both 
small and large vessels via nitric oxide mediated pathways. 35 Insulin resistance results in 
inappropriate intracellular pathway activation leading to the opposite effects, which in the 
vascular endothelium leads to vasoconstriction. Ex-vivo vascular ring models from equine 
digital vessels showed that just 30 minutes pre-incubation in insulin (inducing insulin 
dysfunction) resulted in an inappropriate vasoconstriction response to the addition of insulin. 
36 This effect was obliterated by a blocker of the inappropriate intracellular pathway of 
insulin signaling. 36 Further work in horse vasculature has supported this first study finding 
the same results using laminar vessels. 37 This was further supported by comparing the 
vascular responses from naturally occurring endocrinopathic laminitis horses and controls 
using laminar arteries and veins and facial arteries. 38 Vascular dysfunction was evident in the 
vessels derived from endocrinopathic animals but not the controls. 38 Together there is now 
compelling evidence that hyperinsulinemia associated with either the hyperinsulinemia model 
or naturally occurring insulin dysregulation induces abnormal insulin signaling at a cellular 
level, at least in the vascular endothelium.  
However, the vascular endothelium is only part of the story and does not correlate well with 
the histological lesion which provides even more important mechanistic clues. 1 As early as 6 
hours post exposure to hyperinsulinemia, marked elongation of the secondary epidermal 
laminae (SEL) is observed, developing tapered tips and with SEL angled more acutely to the 
primary lamellar (PEL) axis. 39 Cellular changes are dominated by cellular elongation and 
stretching then apoptosis and mitosis, all of which precede the pain and inflammation of Obel 
grade 2 laminitis. 40 The current theory of endocrinopathic laminitis is that the epithelial cells 
that make up the laminae are affected by hyperinsulinaemia, just like the vascular endothelial 
cells were shown to be affected above, resulting in abnormal intracellular signaling in insulin 
dysregulated horses. This results in activation and dysregulation of certain pathways or 
‘downstream events’ within the cells resulting in cellular damage and disruption of 
cytoskeletal organisation, allowing these cells to stretch under mechanical forces and leading 
to the well-defined initial lesion of laminar and cellular stretching. 1, 41   
PPID and insulin dysregulation  
Although it is known that over a third of horses with PPID are insulin dysregulated, and that 
insulin dysregulation causes the laminitis, it is not entirely clear how PPID induces insulin 
dysregulation. Due to the high prevalence of PPID (over 20%) 23 and also of insulin 
dysregulation without PPID (EMS; over 25% in susceptible breeds such as ponies) 42, and the  
fact that in both conditions the prevalence increases with age 23, 42 it is possible that both 
conditions could simply be occurring in the same animal. It may be that PPID itself does not 
cause insulin dysregulation at all and laminitis only occurs when PPID occurs in an animal 
that already had insulin dysregulation. However, this is not supported by the observation that 
horses with PPID were 2.7 times more likely to have hyperinsulinemia than aged matched 
controls. 23  
Several mechanisms have been considered as to why PPID may lead to insulin dysregulation 
including abnormal central or peripheral glucocorticoid activity. 17 Although much of the 
secreted ACTH in horses with PPID may be biologically inactive or inert 19 and circulating 
cortisol may not be elevated in horses with PPID 43, there could be local upregulation of 
corticosteroids in peripheral tissues such as adipose tissue. 17 Evidence for prolonged 
glucocorticoid administration inducing insulin dysregulation exists. 44 Or it could be that 
pituitary peptides such as CLIP interfere with insulin regulation. 19 But ultimately, the 
relationship between PPID and the development of insulin dysregulation is not completely 
known.  
Irrespective of how horses with PPID develop insulin dysregulation, it is increasingly 
apparent that the combination of PPID and insulin dysregulation leads to a poorer prognosis 
than either PPID horses without insulin dysregulation 45 or than insulin dysregulated horses 
without PPIDi.   
Conclusions and clinical implications  
Laminitis is a clinical syndrome with a cause, and endocrinopathic laminitis accounts for over 
90% of laminitis cases seen in the field for lameness. Therefore, for laminitis that presents as 
lameness, clinical evaluation can often rapidly eliminate SIRS and sepsis associated 
conditions and supporting limb laminitis as potential causes. If these are ruled out, efforts to 
appropriately diagnose the underlying endocrinopathy should be made. Specifically, clinical 
examination and diagnostic testing can be used to determine if the horse has EMS, PPID or 
PPID with insulin dysregulation. Veterinarians should be aware that horses with PPID may 
not be presented with clinical laminitis or a history of laminitis, but hooves should be 
checked for evidence of sub-clinical laminitis in the form of divergent hoof rings, dropped 
soles or separation at the white line) due to the possibility of these being missed by their 
owners.  
It is important to assess insulin regulation in horses with PPID, as the presence of insulin 
dysregulation can guide determination of the likelihood of laminitis as well as the prognosis. 
Where insulin dysregulation is not well controlled, the prognosis for long term survival is 
lower. Knowledge of the relationship between insulin dysregulation and laminitis can direct 
veterinarians to utilize the results of the diagnostic tests for insulin dysregulation (and PPID) 
to guide longer term management.  
Veterinarians should utilize the understanding of the early lesion of stretching due to cellular 
compromise in laminae to guide clinical management of horses with endocrinopathic 
laminitis. Management changes that should be considered include providing hoof support , 
thereby limiting mechanical forces and providing dietary and pharmacologic intervention to 
reduce circulating hyperinsulinemia as rapidly as possible.  
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